PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 27, 2026Immunotherapy0 citations

First-line treatments for metastatic non-small-cell lung cancer with sugemalimab plus chemotherapy: a China-based cost-effectiveness analysis

View Full Paper
ZZZixuan ZhangKMKehui MengMWM WU

Key Points

  • To evaluate the cost-effectiveness of sugemalimab combined with platinum-based chemotherapy for metastatic non-small-cell lung cancer (NSCLC) in China.
  • Evaluated the clinical benefits and cost-effectiveness of sugemalimab plus chemotherapy.
  • Considered the impact of PD-L1 expression on treatment targeting.
  • Analyzed the effects of potential policy changes on drug pricing.
  • Sugemalimab plus chemotherapy is not currently cost-effective at existing price points.
  • Targeting patients with high PD-L1 expression could improve cost-effectiveness.
  • Adjusting reimbursement policies and drug pricing is necessary for better outcomes.

Abstract

Sugemalimab plus platinum-based chemotherapy offers long-term clinical benefits for metastatic NSCLC but is not cost-effective at current prices in China. Improving cost-effectiveness may require targeting patients with high PD-L1 expression, adjusting reimbursement policies, and reducing drug prices.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Zhang et al. (2026) studied this question.

synapsesocial.com/papers/69eefd82fede9185760d4288https://doi.org/10.1080/1750743x.2026.2660567
Ask AI
Helpful
Bookmark
Share
View Full Paper